Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2009

View Archived Issues

Experiments show TGR5 can be targeted with INT-777 for diabetes and obesity

LEO-29102 cream evaluated in healthy and psoriatic subjects in phase I and II trials

Antibacterial agent GSK-1322322 currently evaluated in phase I and II trials by GSK

Preclinical data on novel lysosomotropic cathepsin K inhibitors presented by Medvir

DAS-181 shows potent preclinical activity against H1N1, H5N1 and seasonal influenza virus

New alliance seeks to measure tumor response to protein kinase inhibitors

Sirona Biochem reports test results for sodium/glucose cotransporter inhibitors

Alligator Bioscience enters into antibody research agreement with BioInvent

PTH-CBD fusion protein reduces chemotherapy-induced osteoporosis in mice

ORM-11984 effective in rat models of osteopenia and osteoporosis

Mologen reaches milestone in MGN-1703 clinical cancer study

Chugai files application for approval of Tarceva for pancreatic cancer in Japan

Novel compounds claimed by The Salk Institute for acute neural injury therapy

Casein kinase II inhibitors described by Bristol-Myers Squibb as oncolytics

Sequenom launches SensiGene cystic fibrosis carrier screening test

Dual PDE4 inhibitors and mAChR agonists in early development at GSK

Meridian Bioscience cleared to update the Tru Flu package insert

Phase IIb results reported for GSK-1838262 in neuropathic pain

Panvax H1N1 vaccine approved for use in Australia

Johnson & Johnson and Elan closing transaction for Alzheimer's immunotherapy program

Neogenix obtains IND clearance to commence phase I NPC-1C trials

Karo Bio expands thyroid hormone receptor platform

Incyte reports encouraging topline phase IIb results for INCB-18424 in psoriasis

Rexahn and Teva close a license agreement for RX-3117

Impax reports results of phase II IPX-066 trial in Parkinson's disease

BioCryst awarded grant by Department of Health & Human Services for peramivir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...